This article is more than 5 years old. Information may no longer be current.

Aerie initiates phase 2b study of glaucoma drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals has initiated a phase 2b study of a novel drug for the treatment of glaucoma, according to a press release.

PG324 is a fixed-combination of Aerie’s AR-13324 and latanoprost, the release said.

The study will be conducted on approximately 300 patients with glaucoma or ocular hypertension over the course of 28 days. Two concentrations of PG324 will be compared with latanoprost and AR-13324, separately, all dosed once daily. The primary outcome measure will be PG324’s efficacy compared with each of its components, in terms of decreases in mean diurnal IOP, according to the release.

Top-line results are expected in mid-2014.